Theriva Biologics, Inc.(TOVX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $2.6M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
TOVX Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Theriva Biologics, Inc. (TOVX), a Healthcare sector company. TOVX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $2.6m in revenue and is scored on the micro-cap board instead. Top institutional holders of TOVX by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, JANE STREET GROUP, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. TOVX trades on the NYSE exchange and files with the SEC under CIK 894158. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TOVX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Theriva Biologics, Inc. directly from SEC EDGAR.
Revenue
Q2 2026
$0.00
Net Income
Q2 2026
$-3.2M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
+7.5% YoYOperating Income
+8.7% YoYEPS (Diluted)
+89.1% YoYTotal Assets
+8.2% YoYTotal Debt
+1716.3% YoYOp. Cash Flow
+1.6% YoYFree Cash Flow
+1.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-23.7M +7.5% | $-25.7M -39.8% | $-18.3M +6.8% | $-19.7M -38.0% | $-14.3M -42.1% | $-10.0M |
| Operating Income | $-24.1M +8.7% | $-26.3M -22.9% | $-21.4M +0.7% | $-21.6M -51.2% | $-14.3M -40.5% | $-10.2M |
| EPS (Diluted) | $-2.08 +89.1% | $-19.03 -1570.5% | $-1.14 -2074.0% | $-0.05 -589.5% | $-0.01 -192.3% | $-0.00 |
| Total Assets | $38.2M +8.2% | $35.4M -36.0% | $55.2M -23.2% | $71.9M +2.1% | $70.4M +736.7% | $8.4M |
| Total Debt | $1.7M +1716.3% | $92.0K -59.1% | $225.0K -19.1% | $278.0K | — | — |
| Operating Cash Flow | $-16.7M +1.6% | $-16.9M +10.8% | $-19.0M +0.5% | $-19.1M -48.0% | $-12.9M -5.9% | $-12.2M |
| Free Cash Flow | $-16.7M +1.4% | $-16.9M +11.8% | $-19.2M +0.0% | $-19.2M -48.8% | $-12.9M -6.0% | $-12.2M |
Get alerted when TOVX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Theriva Biologics, Inc. including:
Top Institutional Holders of TOVX
VANGUARD CAPITAL MANAGEMENT LLC
$121.5K486,179 shJANE STREET GROUP, LLC
$83.0K331,922 shGEODE CAPITAL MANAGEMENT, LLC
$73.6K294,021 shVANGUARD FIDUCIARY TRUST CO
$60.4K241,780 shIkarian Capital, LLC
$28.0K112,076 shVirtu Financial LLC
$22.0K87,138 shNORTHERN TRUST CORP
$20.7K82,700 shRENAISSANCE TECHNOLOGIES LLC
$15.9K63,710 shUBS Group AG
$15.3K61,053 shXTX Topco Ltd
$13.5K53,868 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $121.5K | 486,179 |
| JANE STREET GROUP, LLC | $83.0K | 331,922 |
| GEODE CAPITAL MANAGEMENT, LLC | $73.6K | 294,021 |
| VANGUARD FIDUCIARY TRUST CO | $60.4K | 241,780 |
| Ikarian Capital, LLC | $28.0K | 112,076 |
| Virtu Financial LLC | $22.0K | 87,138 |
| NORTHERN TRUST CORP | $20.7K | 82,700 |
| RENAISSANCE TECHNOLOGIES LLC | $15.9K | 63,710 |
| UBS Group AG | $15.3K | 61,053 |
| XTX Topco Ltd | $13.5K | 53,868 |
More Healthcare Companies
View all Healthcare →Put TOVX on your watchlist
Track score changes the day Theriva Biologics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TOVX a good stock to buy?
13F Pro's AI-powered analysis of Theriva Biologics, Inc. (TOVX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TOVX are available on the TOVX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TOVX is classified as a small company.
Which hedge funds own TOVX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TOVX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Theriva Biologics, Inc.'s investment landscape.